Screener
Monopar Therapeutics MNPR Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | For the Three Months Ended / March 31, 2026 | For the Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchase of short-term investments | (40,837,552) | (1,925,828) |
| Maturities of short-term investments | 35,254,000 | 1,600,000 |
| Net cash provided by (used in) investing activities | (5,583,552) | (325,828) |
| Cash flows from financing activities: | ||
| Taxes paid related to net share settlement of vested restricted stock units | (200,203) | (131,129) |
| Cash proceeds from the issuance of stock upon exercise of stock options | — | 15,447 |
| Net cash provided by (used in) financing activities | (200,203) | (115,682) |
Document
FAQ
- What is Monopar Therapeutics's investing cash flow?
- Monopar Therapeutics (MNPR) reported investing cash flow of -$5.58M in Q1 2026.
- How has Monopar Therapeutics's investing cash flow changed year-over-year?
- Monopar Therapeutics's investing cash flow decreased by 1613.7% year-over-year, from -$325.83K to -$5.58M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Monopar Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude